That is the useful signal for anyone taking omega-3 “for the brain.” A biomarker can move without producing a measurable cognitive benefit. For cognitive performance, that distinction matters more than the supplement label.
DHA reached the brain. Performance did not move.
The study, published in eBioMedicine and reported by AOL.com, tested high-dose docosahexaenoic acid — DHA, an omega-3 fatty acid that is a structural component of brain cell membranes.
The trial design was not casual wellness marketing:
- 365 relatively healthy adults.
- Ages 55 to 80.
- No cognitive impairment at baseline.
- Low dietary DHA intake: under 200 milligrams per day.
- At least one cardiovascular or dementia-related risk factor.
- Random assignment to either 2 grams per day of DHA or placebo.
- Duration: 24 months.
- DHA in cerebrospinal fluid measured after 6 months.
- Cognitive performance and brain-structure markers tracked over the two-year period.
Researchers also tested for the APOE ε4 gene variant, described in the source as the strongest known genetic risk factor for Alzheimer’s disease, because the trial examined whether genotype affected DHA metabolism or response.
The mechanistic result was clear: high-dose DHA significantly increased DHA levels in cerebrospinal fluid after six months, regardless of APOE ε4 status.
The clinical-performance result was less convenient: no observed improvement in cognitive performance or markers of brain structure over 24 months, in carriers or noncarriers.
That is not “omega-3 does nothing.” It is narrower and more important: in this sample, at this dose, over this time window, improved DHA delivery did not translate into measured cognitive or structural benefit.
Why this matters for brain-health decisions
The commercial claim around omega-3 often compresses three separate propositions into one:
1. DHA is biologically relevant to the brain.
2. Oral supplementation increases DHA availability.
3. Higher DHA availability improves cognition or protects brain structure.
This trial supports the second point. It does not support the third.
That gap is where many brain-health interventions become overconfident. A molecule can be necessary for neural tissue and still fail to produce measurable gains when added as a supplement in a given population. The brain is not a single-deficiency machine. Working memory, processing capacity, and age-related cognitive resilience depend on distributed systems, not one nutrient lever.
For patients or clients considering supplementation, the immediate practical question is not “Is DHA good or bad?” It is: what outcome are you trying to buy?
If the goal is to correct low intake or meet a nutrition target, that is one decision. If the goal is measurable cognitive enhancement or Alzheimer’s-risk modification, this study does not provide that proof. The relevant documents to check are therefore basic but often skipped:
- the actual DHA dose per serving, not just “fish oil” on the label;
- whether the product specifies DHA separately from EPA;
- the intended endpoint: nutrient intake, cognition, or disease-risk strategy;
- whether a clinician has tied supplementation to an individual risk profile rather than a generic brain-health claim.
The stronger signal may be structural, not supplemental
A separate study reported by PsyPost points in a different direction: brain structure itself remains tightly linked to working-memory performance in aging adults.
That study, published in Neuropsychology, analyzed neuroimaging data from 30,640 healthy adults aged 51 to 80 in the UK Biobank. It found that greater tissue volume in six specific brain areas predicted stronger working memory.
Working memory is the system used to hold and manipulate information in real time: following conversations, planning, reading comprehension, mental arithmetic, decision-making. It tends to decline with age. The study used a computerized Numeric Memory Test, including the kind of digit-span task that requires temporary storage and active manipulation.
The important comparison is not “supplements versus scans.” It is mechanism versus outcome.
The DHA trial changed a biochemical availability marker without moving measured cognition. The neuroimaging study links preserved brain tissue volume with working-memory strength in a very large aging sample. That does not prove an intervention, but it clarifies the performance target: preserve the systems that support executive control, verbal-auditory storage, and active manipulation.
Measured takeaway: do not treat a raised brain nutrient level as a proxy for cognitive benefit. If the objective is cognitive performance, demand endpoints that look like cognition — working memory, structural preservation, functional capacity — not just improved delivery of a biologically plausible compound.